Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-9

yeah agree. $5.5m not a lot, the accent trial will burn through a lot now, once you expand a trial to other countries costs ramp up quickly with a CRO running it. these CROs ain't charities and I've heard stories of them charging like wounded bulls..
//and a USA trial won't be cheap, they typically charge a lot over there, more than Europe.
//it is possible to get an IND but choose not to do a trial in US, I've heard anecdotally of companies just getting the IND for purposes of kudos having an FDA tick for your drug's profile, but then run a trial elsewhere. what I don't understand is why didn't they bolt on the folfirox /AMP combination onto Accent as a kind of parallel study, might have been more efficient and cost-effective?